Pharmacogenomic evaluation of CYP2C19 alleles linking low clopidogrel response and the risk of acute coronary syndrome in Indians
The Journal of Gene Medicine · 2024-01 · 26 (1)
DOI: 10.1002/jgm.3634 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, online erschienen am 20.11.2023. Verfasst von Keshavamurthy Ganapathy Bhat und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Army Hospital, Research and Referral, New Delhi, India. Hauptthemen laut MEDLINE: Ticlopidine, Acute Coronary Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
Clopidogrel is an antiplatelet drug widely prescribed to prevent atherothrombotic events in coronary artery disease patients. However, there is evidence to suggest that the effectiveness of clopidogrel varies owing to genetic diversity in CYP2C19 . This heterogeneity in South Asians, who are also known to have high risk of cardiac events than other population groups, highlights the importance of investigating CYP2C19 variants to estimate the risk proportion in the groups.
Methods
Given the high prevalence and genetic heterogeneity, the population‐based case control was conducted in a cohort of 1191 subjects comprising 645 acute coronary syndrome (ACS) cases (unstable angina, ST‐elevation myocardial infarction, and non‐ST‐elevation myocardial infarction) and 546 healthy controls of South Asian Indian origin. The metabolization status of CYP2C19 was assessed using *2, *3 and *17 variants in the stated cohorts to determine the prevalence of metabolization and its association with phenotypes.
Results
The results suggest a possible genetic association between studied CYP2C19 polymorphisms and ACS, since there was a higher proportion of intermediate and poor metabolizers present in the studied cohorts. The association analyses revealed that the *2 allele of CYP2C19 confers a significant risk for ACS, while the *17 allele provides protection.
Conclusions
These findings contribute to the understanding of CYP2C19 genetic variants and their impact on clopidogrel response in South Asian Indians. Additionally, they underline the significance of assessing CYP2C19 variations in patients receiving clopidogrel therapy in order to improve therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Army Hospital, Research and Referral, New Delhi, India.
- NMC Genetics India Pvt. Ltd, Gurugram, Haryana, India.
- Lab Division, NMC Healthcare, Abu Dhabi, UAE.
ORCID-Profile: Varun Sharma
Zitieren
APA
Bhat, K. G., Pillai, R. K. J., Lodhi, H., Guleria, V. S., Abbot, A. K., Gupta, L., Rastogi, G., Sharma, A., Mohammed, Z., & Sharma, V. (2024). Pharmacogenomic evaluation of CYP2C19 alleles linking low clopidogrel response and the risk of acute coronary syndrome in Indians. The Journal of Gene Medicine, 26(1). https://doi.org/10.1002/jgm.3634
Vancouver
Bhat KG, Pillai RKJ, Lodhi H, Guleria VS, Abbot AK, Gupta L, et al. Pharmacogenomic evaluation of CYP2C19 alleles linking low clopidogrel response and the risk of acute coronary syndrome in Indians. The Journal of Gene Medicine. 2024;26(1). doi:10.1002/jgm.3634
BibTeX
@article{Bhat2024,
author = {Bhat, Keshavamurthy Ganapathy and Pillai, Ratheesh Kumar Janardhana and Lodhi, Heemanshu and Guleria, Vivek Singh and Abbot, Anil Kumar and Gupta, Love and Rastogi, Garima and Sharma, Anuka and Mohammed, Zafar and Sharma, Varun},
title = {Pharmacogenomic evaluation of CYP2C19 alleles linking low clopidogrel response and the risk of acute coronary syndrome in Indians},
journal = {The Journal of Gene Medicine},
year = {2024},
volume = {26},
number = {1},
doi = {10.1002/jgm.3634}
}
EUVIMED